Natera Slides as Investors Digest Insider Sales After a Strong Run

Natera (NTRA) is down 5.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears to be more of a sentiment-driven pullback than a reaction to a clear negative operating update. This could be because investors are taking profits after a sharp rally, while recent insider-sale disclosures and sale notices added near-term pressure even as the company continued to announce new clinical-trial progress.

Details:

Natera announced on October 5 the launch of the phase III AFT-70 NAVIGATE study, which will use Signatera Genome in a molecular residual disease-guided breast cancer treatment strategy and is expected to enroll more than 2,000 patients across roughly 200 sites.

In mid-September, the company highlighted new lung-cancer data involving more than 1,100 patients, reinforcing the recent bullish case around Signatera and helping explain why the stock had already run up sharply before today’s decline.

In second-quarter results released in August, revenue rose 37.7% year over year to $752.8 million, oncology test volume jumped 57.2%, and management raised full-year 2026 revenue guidance to a range of $2.85 billion to $2.91 billion.

Recent SEC filings showed stock sales by senior executives under Rule 10b5-1 plans, including filings dated October 2 and October 3, along with Form 144 sale notices dated October 1, which may have weighed on momentum traders.

Sources:

Natera, SEC, Yahoo Finance, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$NTRA Insider Trading Activity

$NTRA insiders have traded $NTRA stock on the open market 265 times in the past 6 months. Of those trades, 0 have been purchases and 265 have been sales.

Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:

MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 65 sales selling 265,157 shares for an estimated $75,850,279.
JONATHAN SHEENA has made 0 purchases and 80 sales selling 62,053 shares for an estimated $19,441,407.
ROELOF BOTHA has made 0 purchases and 6 sales selling 78,000 shares for an estimated $17,184,092.
DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 22 sales selling 54,812 shares for an estimated $14,052,243.
STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 28 sales selling 59,681 shares for an estimated $13,838,169.
SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 33 sales selling 40,023 shares for an estimated $11,583,173.
HERM ROSENMAN sold 16,530 shares for an estimated $4,132,500
JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 8 sales selling 11,942 shares for an estimated $3,310,904.
MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 16 sales selling 11,717 shares for an estimated $2,666,293.
GAIL BOXER MARCUS has made 0 purchases and 4 sales selling 11,000 shares for an estimated $2,389,328.
ROWAN E CHAPMAN has made 0 purchases and 2 sales selling 3,099 shares for an estimated $679,636.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$NTRA Hedge Fund Activity

We have seen 486 institutional investors add shares of $NTRA stock to their portfolio, and 295 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 12,865,346 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,492,298,171
PRICE T ROWE ASSOCIATES INC /MD/ removed 3,162,981 shares (-26.0%) from their portfolio in Q2 2026, for an estimated $858,591,192
FMR LLC added 2,897,142 shares (+113.4%) to their portfolio in Q2 2026, for an estimated $786,429,195
GOLDMAN SACHS GROUP INC added 952,921 shares (+124.2%) to their portfolio in Q2 2026, for an estimated $258,670,405
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 806,536 shares (+inf%) to their portfolio in Q2 2026, for an estimated $218,934,197
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 795,962 shares (+242.8%) to their portfolio in Q2 2026, for an estimated $216,063,884
WELLINGTON MANAGEMENT GROUP LLP removed 727,855 shares (-15.3%) from their portfolio in Q2 2026, for an estimated $197,576,239

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$NTRA Government Contracts

We have seen $791,200 of award payments to $NTRA over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

DNA TESTING: $230,000
TUMOR WHOLE EXOME SEQUENCING (WES) AND PERIPHERAL BLOOD CTDNA TEST TESTING (SINGLE ASSAY) SERVICES AND WES ...: $80,400

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$NTRA Analyst Ratings

Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 06/23/2026
William Blair issued a "Outperform" rating on 04/14/2026

To track analyst ratings and price targets for $NTRA, check out Quiver Quantitative's $NTRA forecast page.

$NTRA Price Targets

Multiple analysts have issued price targets for $NTRA recently. We have seen 11 analysts offer price targets for $NTRA in the last 6 months, with a median target of $275.0.

Here are some recent targets:

Tejas Savant from Morgan Stanley set a target price of $310.0 on 07/09/2026
Daniel Markowitz from Evercore ISI Group set a target price of $300.0 on 07/06/2026
Subbu Nambi from Guggenheim set a target price of $290.0 on 06/29/2026
Eve Burstein from Bernstein set a target price of $310.0 on 06/26/2026
Luke Sergott from Barclays set a target price of $260.0 on 06/24/2026
Mark Massaro from BTIG set a target price of $275.0 on 06/24/2026
Dan Leonard from RBC Capital set a target price of $275.0 on 06/11/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.